Novartis Buys UK Biotech Myricx Bio in $1.5B Cancer Drug Deal
Novartis is acquiring Myricx Bio for up to $1.5B to strengthen its next-gen cancer drug pipeline using the startup's novel ADC payload technology.
Novartis is making a big bet on the future of cancer treatment, agreeing to acquire London-based biotech Myricx Bio for up to $1.5 billion. The deal includes $1.1 billion in cash paid upfront, with the remaining amount tied to potential milestone payments — meaning Myricx could earn more if its technology hits certain development targets down the road.
So what exactly does Myricx Bio bring to the table? The company specializes in a cutting-edge class of cancer-fighting technology called antibody-drug conjugates, or ADCs. Think of ADCs as guided missiles — they attach to cancer cells specifically and deliver a toxic payload directly to the tumor, sparing healthy tissue. Myricx's edge is its novel NMTi platform, which focuses on developing the "warhead" part of that missile in a new and potentially more effective way.
Read more Novartis to Acquire Myricx Bio for Up to $1.5 Billion →
For Novartis, one of the world's largest pharmaceutical companies, this acquisition is a chance to get ahead in what has become one of the hottest areas in oncology. ADC drugs have attracted massive investment across the industry in recent years, and snagging a specialized payload developer early could give Novartis a meaningful competitive advantage as it builds out its cancer portfolio.
Myricx Bio, despite being UK-headquartered, operates at the intersection of cutting-edge chemistry and oncology biology — a niche that big pharma has been eager to snap up. Deals like this one highlight how smaller, science-focused biotechs are increasingly becoming prime acquisition targets as larger companies look to replenish their drug pipelines with genuinely novel approaches rather than incremental improvements on existing therapies.
Continue reading at GlobalNewswire.
